Radiotherapy and the tumor stroma: The importance of dose and fractionation

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Hellevik, Turid ^a,b   Martinez Zubiaurre, Iñigo ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Angiogenesis; Cancer associated fibroblasts; Cancer immunity; Hypoxia; Stereotactic ablative radiotherapy; Tumor microenvironment

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ANGIOGENESIS; APOPTOSIS; CANCER RADIOTHERAPY; DOSIMETRY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); RADIATION DOSE FRACTIONATION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84893706331     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00001     Document Type: Review

References (164)

1. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer (2004) 4:737-47. doi:10.1038/nrc1451
2. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer (2011) 11:239-53. doi:10.1038/nrc3007
3. De Ruysscher D, Belderbos J, Reymen B, van Elmpt W, van Baardwijk A, Wanders R, et al. State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clin Lung Cancer (2013) 14:89-95. doi:10.1016/j.cllc.2012.06.006
4. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol (2010) 7:44-54. doi:10.1038/nrclinonc.2009.188
5. Salama JK, Kirkpatrick JP, Yin FF. Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 9:654-65. doi:10.1038/nrclinonc.2012.166
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
7. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:309-22. doi:10.1016/j.ccr.2012.02.022
8. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer (2005) 5:867-75. doi:10.1038/nrc1735
9. Chargari C, Clemenson C, Martins I, Perfettini JL, Deutsch E. Understanding the functions of tumor stroma in resistance to ionizing radiation: emerging targets for pharmacological modulation. Drug Resist Updat (2013) 16:10-21. doi:10.1016/j.drup.2013.01.001
10. Good JS, Harrington KJ. The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin Oncol (R Coll Radiol) (2013) 25:569-77. doi:10.1016/j.clon.2013.06.009
11. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer (2001) 1:46-54. doi:10.1038/35094059
12. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 114:589-95. doi:10.1182/blood-2009-02-206870
13. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res (2012) 177:311-27. doi:10.1667/RR2773.1
14. Hellevik T, Pettersen I, Berg V, Bruun J, Bartnes K, Busund LT, et al. Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Transl Oncol (2013) 6:66-74. doi:10.1593/tlo.13640
15. Coutard H. Roentgentherapy of epitheliomas of the tonsillar region; hypopharynx and larynx from 1920 to 1926. Am J Roentgenol (1932) 28:313-31 and 343-348.
16. De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol (2010) 28:5301-10. doi:10.1200/JCO.2010.30.3271
17. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2004) 60:1026-32. doi:10.1016/j.ijrobp.2004.07.701
18. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand (1951) 102:316-9.
19. Sturm V, Kober B, Höver KH, Schlegel W, Boesecke R, Pastyr O, et al. Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. Int J Radiat Oncol Biol Phys (1987) 13:279-82. doi:10.1016/0360-3016(87)90140-4
20. Kelly PJ, Lin YB, Yu AY, Alexander BM, Hacker F, Marcus KJ, et al. Stereotactic irradiation of the postoperative resection cavity for brain metastasis: a frameless linear accelerator-based case series and review of the technique. Int J Radiat Oncol Biol Phys (2012) 82:95-101. doi:10.1016/j.ijrobp.2010.10.043
21. Maranzano E, Trippa F, Casale M, Costantini S, Anselmo P, Carletti S, et al. Reirradiation of brain metastases with radiosurgery. Radiother Oncol (2012) 102:192-7. doi:10.1016/j.radonc.2011.07.018
22. Wegner RE, Leeman JE, Kabolizadeh P, Rwigema JC, Mintz AH, Burton SA, et al. Fractionated stereotactic radiosurgery for large brain metastases. Am J Clin Oncol (2013). doi:10.1097/COC.0b013e31828aadac
23. Minniti G, Esposito V, Clarke E, Scaringi C, Lanzetta G, Salvati M, et al. Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys (2013) 86:623-9. doi:10.1016/j.ijrobp.2013.03.037
24. Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, et al. Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys (2011) 81:483-9. doi:10.1016/j.ijrobp.2010.05.033
25. Wiggenraad R, Verbeek-de Kanter A, Kal HB, Taphoorn M, Vissers T, Struikmans H. Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol (2011) 98:292-7. doi:10.1016/j.radonc.2011.01.011
26. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol (1995) 34:861-70. doi:10.3109/02841869509127197
27. Potters L, Gaspar LE, Kavanagh B, Galvin JM, Hartford AC, Hevezi JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for image-guided radiation therapy (IGRT). Int J Radiat Oncol Biol Phys (2010) 76:319-25. doi:10.1016/j.ijrobp.2009.09.041
28. Heinzerling JH, Kavanagh B, Timmerman RD. Stereotactic ablative radiation therapy for primary lung tumors. Cancer J (2011) 17:28-32. doi:10.1097/PPO.0b013e31820a7f80
29. Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol (2011) 23:133-9. doi:10.1097/CCO.0b013e328341ee11
30. Kavanagh BD, Miften M, Rabinovitch RA. Advances in treatment techniques: stereotactic body radiation therapy and the spread of hypofractionation. Cancer J (2011) 17:177-81. doi:10.1097/PPO.0b013e31821f7dbd
31. Timmerman RD, Fernando HC. A radiation oncologist's and thoracic surgeon's view on the role of stereotactic ablative radiotherapy for operable lung cancer. Semin Thorac Cardiovasc Surg (2013) 25:8-13. doi:10.1053/j.semtcvs.2013.01.006
32. Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol (2013) 106:276-82. doi:10.1016/j.radonc.2013.01.004
33. Nuyttens JJ, van derVoort van Zyp NC, Praag J, Aluwini S, van Klaveren RJ, Verhoef C, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol (2012) 102:383-7. doi:10.1016/j.radonc.2011.12.023
34. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 117:4060-9. doi:10.1002/cncr.25997
35. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol (2011) 21:264-70. doi:10.1016/j.semradonc.2011.05.006
36. Liu E, Stenmark MH, Schipper MJ, Balter JM, Kessler ML, Caoili EM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol (2013) 6:442-6. doi:10.1593/tlo.12448
37. Dewas S, Bibault JE, Mirabel X, Fumagalli I, Kramar A, Jarraya H, et al. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol (2012) 7:166. doi:10.1186/1748-717X-7-166
38. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol (2012) 5:404-7. doi:10.1593/tlo.12280
39. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys (2008) 71:484-90. doi:10.1016/j.ijrobp.2007.11.046
40. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 13:395-402. doi:10.1016/S1470-2045(11)70384-9
41. Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies. J Thorac Dis (2011) 3:189-96. doi:10.3978/j.issn.2072-1439.2011.05.03
42. Brown JM, Diehn M, Loo BW Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys (2010) 78:323-7. doi:10.1016/j.ijrobp.2010.04.070
43. Trakul N, Chang CN, Harris J, Chapman C, Rao A, Shen J, et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys (2012) 84:231-7. doi:10.1016/j.ijrobp.2011.10.071
44. Brown JM, Brenner DJ, Carlson DJ. Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2013) 85:1159-60. doi:10.1016/j.ijrobp.2012.11.003
45. Thames HD Jr, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys (1982) 8:219-26. doi:10.1016/0360-3016(82)90517-X
46. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys (1982) 8:1981-97. doi:10.1016/0360-3016(82)90459-X
47. Travis EL, Tucker SL. Isoeffect models and fractionated radiation therapy. Int J Radiat Oncol Biol Phys (1987) 13:283-7. doi:10.1016/0360-3016(87)90141-6
48. Brenner DJ, Sachs RK, Peters LJ, Withers HR, Hall EJ. We forget at our peril the lessons built into the alpha/beta model. Int J Radiat Oncol Biol Phys (2012) 82:1312-4. doi:10.1016/j.ijrobp.2011.12.045
49. Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol (2008) 18:234-9. doi:10.1016/j.semradonc.2008.04.004
50. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 18:240-3. doi:10.1016/j.semradonc.2008.04.005
51. Otsuka S, Shibamoto Y, Iwata H, Murata R, Sugie C, Ito M, et al. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor. Int J Radiat Oncol Biol Phys (2011) 81:1538-43. doi:10.1016/j.ijrobp.2011.05.034
52. Stuschke M, Pottgen C. Altered fractionation schemes in radiotherapy. Front Radiat Ther Oncol (2010) 42:150-6. doi:10.1159/000262470
53. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys (2008) 70:847-52. doi:10.1016/j.ijrobp.2007.10.059
54. Guerrero M, Li XA. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol (2004) 49:4825-35. doi:10.1088/0031-9155/49/20/012
55. Brenner DJ, Hlatky LR, Hahnfeldt PJ, Hall EJ, Sachs RK. A convenient extension of the linear-quadratic model to include redistribution and reoxygenation. Int J Radiat Oncol Biol Phys (1995) 32:379-90. doi:10.1016/0360-3016(95)00544-9
56. Strigari L, Benassi M, Sarnelli A, Polico R, D'Andrea M. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC). Med Phys (2012) 39:4502-14. doi:10.1118/1.4730292
57. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 285:1182-6. doi:10.1056/NEJM197111182852108
58. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol (1984) 23:217-25. doi:10.3109/02841868409136015
59. Kocher M, Treuer H, Voges J, Hoevels M, Sturm V, Müller RP. Computer simulation of cytotoxic and vascular effects of radiosurgery in solid and necrotic brain metastases. Radiother Oncol (2000) 54:149-56. doi:10.1016/S0167-8140(99)00168-1
60. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 293:293-7. doi:10.1126/science.1060191
61. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 300:1155-9. doi:10.1126/science.1082504
62. Fuks Z, Alfieri A, Haimovitz-Friedman A, Seddon A, Cordon-Cardo C. Intravenous basic fibroblast growth factor protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. Cancer J Sci Am (1995) 1:62-72.
63. Ch'ang HJ, Maj JG, Paris F, Xing HR, Zhang J, Truman JP, et al. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med (2005) 11:484-90. doi:10.1038/nm1237
64. Truman JP, García-Barros M, Kaag M, Hambardzumyan D, Stancevic B, Chan M, et al. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One (2010) 5:e12310. doi:10.1371/journal.pone.0012310
65. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 24:589-602. doi:10.1016/j.ccr.2013.09.014
66. Sofia Vala I, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One (2010) 5:e11222. doi:10.1371/journal.pone.0011222
67. Lerman OZ, Greives MR, Singh SP, Thanik VD, Chang CC, Seiser N, et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. Blood (2010) 116:3669-76. doi:10.1182/blood-2009-03-213629
68. Thanik VD, Chang CC, Lerman OZ, Greives MR, Le H, Warren SM, et al. Cutaneous low-dose radiation increases tissue vascularity through upregulation of angiogenic and vasculogenic pathways. J Vasc Res (2010) 47:472-80. doi:10.1159/000313875
69. Siemionow M, Mee J, Porvasnik S, Krapohl BD, Ozer K, Piza P, et al. Effects of 8-Gy radiation on the microcirculation of muscle flaps in the rat. Plast Reconstr Surg (1999) 104:1372-8. doi:10.1097/00006534-199910000-00020
70. Schneider BF, Eberhard DA, Steiner LE. Histopathology of arteriovenous malformations after gamma knife radiosurgery. J Neurosurg (1997) 87:352-7. doi:10.3171/jns.1997.87.3.0352
71. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 120:694-705. doi:10.1172/JCI40283
72. Martin BJ. Inhibiting vasculogenesis after radiation: a new paradigm to improve local control by radiotherapy. Semin Radiat Oncol (2013) 23:281-7. doi:10.1016/j.semradonc.2013.05.002
73. Chen FH, Chiang CS, Wang CC, Fu SY, Tsai CS, Jung SM, et al. Vasculatures in tumors growing from preirradiated tissues: formed by vasculogenesis and resistant to radiation and antiangiogenic therapy. Int J Radiat Oncol Biol Phys (2011) 80:1512-21. doi:10.1016/j.ijrobp.2011.02.055
74. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 275:964-7. doi:10.1126/science.275.5302.964
75. Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fändrich F, Siebert R, et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res (2007) 100:581-9. doi:10.1161/01.RES.0000259562.63718.35
76. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell (2008) 13:193-205. doi:10.1016/j.ccr.2007.11.032
77. Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst (2012) 104:899-905. doi:10.1093/jnci/djs239
78. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res (2010) 70:5679-85. doi:10.1158/0008-5472.CAN-09-4446
79. Russell JS, Brown JM. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol (2013) 4:157. doi:10.3389/fphys.2013.00157
80. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell (2006) 124:175-89. doi:10.1016/j.cell.2005.10.036
81. Kozin SV, Duda DG, Munn LL, Jain RK. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer (2011) 11:532. doi:10.1038/nrc2007-c1
82. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 468:824-8. doi:10.1038/nature09557
83. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 468:829-33. doi:10.1038/nature09624
84. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 108:4274-80. doi:10.1073/pnas.1016030108
85. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res (1999) 59:5863-70.
86. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 8:967-75. doi:10.1038/nrc2540
87. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol (1953) 26:638-48. doi:10.1259/0007-1285-26-312-638
88. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 56:4509-15.
89. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 77:18-24. doi:10.1016/j.radonc.2005.06.038
90. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol (2007) 25:4066-74. doi:10.1200/JCO.2007.12.7878
91. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol (2012) 9:674-87. doi:10.1038/nrclinonc.2012.171
92. Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology (1972) 105:135-42.
93. Ruggieri R, Naccarato S, Nahum AE. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia. Acta Oncol (2010) 49:1304-14. doi:10.3109/0284186X.2010.486796
94. Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys (2011) 79:1188-95. doi:10.1016/j.ijrobp.2010.10.007
95. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 13:206-20. doi:10.1016/j.ccr.2008.01.034
96. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 12:557-67. doi:10.1038/nm0806-978
97. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 121:335-48. doi:10.1016/j.cell.2005.02.034
98. Costello CM, McCullagh B, Howell K, Sands M, Belperio JA, Keane MP, et al. A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease. Eur Respir J (2012) 39:1415-24. doi:10.1183/09031936.00044911
99. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One (2010) 5:e9175. doi:10.1371/journal.pone.0009175
100. Hoffmann F, Müller W, Schütz D, Penfold ME, Wong YH, Schulz S, et al. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues. J Biol Chem (2012) 287:28362-77. doi:10.1074/jbc.M111.335679
101. Zhang XY, Su C, Cao Z, Xu SY, Xia WH, Xie WL, et al. CXCR7 upregulation is required for early endothelial progenitor cell-mediated endothelial repair in patients with hypertension. Hypertension (2014) 63:383-9. doi:10.1161/HYPERTENSIONAHA.113.02273
102. Rödel F, Frey B, Manda K, Hildebrandt G, Hehlgans S, Keilholz L, et al. Immunomodulatory properties and molecular effects in inflammatory diseases of low-dose x-irradiation. Front Oncol (2012) 2:120. doi:10.3389/fonc.2012.00120
103. Kroemer G, Zitvogel L. Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology (2012) 1:407-8. doi:10.4161/onci.20074
104. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 366:925-31. doi:10.1056/NEJMoa1112824
105. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 2:88. doi:10.3389/fonc.2012.00088
106. Santin AD, Hermonat PL, Hiserodt JC, Chiriva-Internati M, Woodliff J, Theus JW, et al. Effects of irradiation on the expression of major histocompatibility complex class I antigen and adhesion costimulation molecules ICAM-1 in human cervical cancer. Int J Radiat Oncol Biol Phys (1997) 39:737-42. doi:10.1016/S0360-3016(97)00372-6
107. Hauser SH, Calorini L, Wazer DE, Gattoni-Celli S. Radiation-enhanced expression of major histocompatibility complex class I antigen H-2Db in B16 melanoma cells. Cancer Res (1993) 53:1952-5.
108. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 203:1259-71. doi:10.1084/jem.20052494
109. Santin AD, Rose GS, Hiserodt JC, Fruehauf J, Eck LM, Garcia RI, et al. Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers. Int J Cancer (1996) 65:688-94. doi:10.1002/(SICI)1097-0215(19960301)65:5<688::AID-IJC21>3.3.CO;2-E
110. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 180:3132-9.
111. Hareyama M, Imai K, Oouchi A, Takahashi H, Hinoda Y, Tsujisaki M, et al. The effect of radiation on the expression of intercellular adhesion molecule-1 of human adenocarcinoma cells. Int J Radiat Oncol Biol Phys (1998) 40:691-6. doi:10.1016/S0360-3016(97)00860-2
112. Sheard MA, Uldrijan S, Vojtesek B. Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells. Cancer Res (2003) 63:7176-84.
113. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 15:5379-88. doi:10.1158/1078-0432.CCR-09-0265
114. Yasuda K, Nirei T, Tsuno NH, Nagawa H, Kitayama J. Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer. Cancer Sci (2011) 102:1257-63. doi:10.1111/j.1349-7006.2011.01940.x
115. Wei S, Egenti MU, Teitz-Tennenbaum S, Zou W, Chang AE. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother (2013) 36:124-32. doi:10.1097/CJI.0b013e31828298e6
116. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ (2008) 15:3-12. doi:10.1038/sj.cdd.4402269
117. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13:1050-9. doi:10.1038/nm1622
118. Du S, Barcellos-Hoff MH. Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor beta activity in carcinomas. Semin Radiat Oncol (2013) 23:242-51. doi:10.1016/j.semradonc.2013.05.001
119. Santin AD, Hiserodt JC, DiSaia PJ, Pecorelli S, Granger GA. Differential effects of high-dose gamma irradiation on the production of transforming growth factor-beta in fresh and established human ovarian cancer. Gynecol Oncol (1996) 61:403-8. doi:10.1006/gyno.1996.0164
120. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest (1994) 93:892-9. doi:10.1172/JCI117045
121. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res (1995) 55:3847-53.
122. Mishra P, NBanerjee D, Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol (2011) 89: doi:10.1189/jlb.0310182
123. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer (2006) 6:392-401. doi:10.1038/nrc1877
124. Hashimoto I, Kodama J, Seki N, Hongo A, Miyagi Y, Yoshinouchi M, et al. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res (2000) 20:4853-6.
125. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 66:605-12. doi:10.1158/0008-5472.CAN-05-4005
126. Tsai CS, Chen FH, Wang CC, Huang HL, Jung SM, Wu CJ, et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys (2007) 68:499-507. doi:10.1016/j.ijrobp.2007.01.041
127. Milas L. Tumor bed effect in murine tumors: relationship to tumor take and tumor macrophage content. Radiat Res (1990) 123:232-6. doi:10.2307/3577551
128. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS, et al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res (2010) 70:1534-43. doi:10.1158/0008-5472.CAN-09-2995
129. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10:942-9. doi:10.1038/nm1093
130. Qinfeng S, Depu W, Xiaofeng Y, Shah W, Hongwei C, Yili W. In situ observation of the effects of local irradiation on cytotoxic and regulatory T lymphocytes in cervical cancer tissue. Radiat Res (2013) 179:584-9. doi:10.1667/RR3155.1
131. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol (2005) 174:7516-23.
132. Norian LA, Rodriguez PC, O'Mara LA, Zabaleta J, Ochoa AC, Cella M, et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 69:3086-94. doi:10.1158/0008-5472.CAN-08-2826
133. Nishisaka N, Maini A, Kinoshita Y, Yasumoto R, Kishimoto T, Jones RF, et al. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J Immunother (1999) 22:308-14. doi:10.1097/00002371-199907000-00004
134. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 71:2488-96. doi:10.1158/0008-5472.CAN-10-2820
135. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol (2012) 189:558-66. doi:10.4049/jimmunol.1200563
136. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2012) 83:1306-10. doi:10.1016/j.ijrobp.2011.09.049
137. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 10:554-67. doi:10.1038/nri2808
138. Kuhlmann UC, Chwieralski CE, Reinhold D, Welte T, Buhling F. Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8. Int J Radiat Biol (2009) 85:138-43. doi:10.1080/09553000802641136
139. Rodningen OK, Overgaard J, Alsner J, Hastie T, Borresen-Dale AL. Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. Radiother Oncol (2005) 77:231-40. doi:10.1016/j.radonc.2005.09.020
140. Tachiiri S, Katagiri T, Tsunoda T, Oya N, Hiraoka M, Nakamura Y. Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. Int J Radiat Oncol Biol Phys (2006) 64:272-9. doi:10.1016/j.ijrobp.2005.08.030
141. Kis E, Szatmári T, Keszei M, Farkas R, Esik O, Lumniczky K, et al. Microarray analysis of radiation response genes in primary human fibroblasts. Int J Radiat Oncol Biol Phys (2006) 66:1506-14. doi:10.1016/j.ijrobp.2006.08.004
142. Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol (2009) 92:299-309. doi:10.1016/j.radonc.2009.06.015
143. Martinez-Zubiaurre I, Fenton C, Taman H, Pettersen I, Hellevik T, Paulssen R. Tumorigenic responses of cancer-associated stromal fibroblasts after ablative radiotherapy: a transcriptome-profiling study. J Cancer Ther (2013) 4:208-50. doi:10.4236/jct.2013.41031
144. Hawsawi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Tweigeri T, et al. Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res (2008) 68:2717-25. doi:10.1158/0008-5472.CAN-08-0192
145. Papadopoulou A, Kletsas D. Human lung fibroblasts prematurely senescent after exposure to ionizing radiation enhance the growth of malignant lung epithelial cells in vitro and in vivo. Int J Oncol (2011) 39:989-99. doi:10.3892/ijo.2011.1132
146. Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, et al. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol (2012) 7:59. doi:10.1186/1748-717X-7-59
147. Rodier F, Coppé JP, Patil CK, Hoeijmakers WA, Muñoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol (2009) 11:973-9. doi:10.1038/ncb1909
148. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol (2011) 192:547-56. doi:10.1083/jcb.201009094
149. Velarde MC, Demaria M, Campisi J. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol (2013) 38:17-27. doi:10.1159/000343572
150. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol (2013) 75:685-705. doi:10.1146/annurev-physiol-030212-183653
151. Friedman N. The effects of irradiation on breast cancer and the breast. CA Cancer J Clin (1988) 38:368-71. doi:10.3322/canjclin.38.6.368
152. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 17:320-9. doi:10.1038/nm.2328
153. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature (2004) 432:332-7. doi:10.1038/nature03096
154. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 5:1597-601. doi:10.4161/cc.5.15.3112
155. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell (2010) 17:135-47. doi:10.1016/j.ccr.2009.12.041
156. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 107:20009-14. doi:10.1073/pnas.1013805107
157. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res (2004) 64:3215-22. doi:10.1158/0008-5472.CAN-03-2464
158. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res (2007) 67:3117-26. doi:10.1158/0008-5472.CAN-06-3452
159. Liu D, Hornsby PJ. Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect. Neoplasia (2007) 9:418-26. doi:10.1593/neo.07205
160. Nikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer (2001) 94:825-33. doi:10.1002/1097-0215(20011215)94:6<825::AID-IJC1545>3.0.CO;2-5
161. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res (2003) 63:8466-75.
162. Kamochi N, Nakashima M, Aoki S, Uchihashi K, Sugihara H, Toda S, et al. Irradiated fibroblast-induced bystander effects on invasive growth of squamous cell carcinoma under cancer-stromal cell interaction. Cancer Sci (2008) 99:2417-27. doi:10.1111/j.1349-7006.2008.00978.x
163. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 68:918-26. doi:10.1158/0008-5472.CAN-07-5714
164. Mantoni TS, Lunardi S, Al-Assar O, Masamune A, Brunner TB. Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-integrin signaling. Cancer Res (2011) 71:3453-8. doi:10.1158/0008-5472.CAN-10-1633